240 related articles for article (PubMed ID: 34833063)
1. Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy.
Roacho-Pérez JA; Garza-Treviño EN; Delgado-Gonzalez P; G-Buentello Z; Delgado-Gallegos JL; Chapa-Gonzalez C; Sánchez-Domínguez M; Sánchez-Domínguez CN; Islas JF
Life (Basel); 2021 Nov; 11(11):. PubMed ID: 34833063
[TBL] [Abstract][Full Text] [Related]
2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
4. Thermosensitive and biodegradable hydrogel encapsulating targeted nanoparticles for the sustained co-delivery of gemcitabine and paclitaxel to pancreatic cancer cells.
Shabana AM; Kambhampati SP; Hsia RC; Kannan RM; Kokkoli E
Int J Pharm; 2021 Jan; 593():120139. PubMed ID: 33278494
[TBL] [Abstract][Full Text] [Related]
5. Recent advances and prospects in gemcitabine drug delivery systems.
Paroha S; Verma J; Dubey RD; Dewangan RP; Molugulu N; Bapat RA; Sahoo PK; Kesharwani P
Int J Pharm; 2021 Jan; 592():120043. PubMed ID: 33152476
[TBL] [Abstract][Full Text] [Related]
6. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
[TBL] [Abstract][Full Text] [Related]
7. Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment.
Nishimoto A
World J Gastroenterol; 2022 Jul; 28(28):3637-3643. PubMed ID: 36161054
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
[TBL] [Abstract][Full Text] [Related]
9. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Li J; Saif MW
JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
[TBL] [Abstract][Full Text] [Related]
11. Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer.
Lei F; Xi X; Rachagani S; Seshacharyulu P; Talmon GA; Ponnusamy MP; Batra SK; Bronich TK
J Control Release; 2021 Feb; 330():1229-1243. PubMed ID: 33217475
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.
Zhang SH; Liu GF; Li XF; Liu L; Yu SN
J Cell Physiol; 2018 Apr; 233(4):3352-3374. PubMed ID: 28926090
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-based combination treatment of pancreatic cancer.
Heinemann V
Semin Oncol; 2002 Feb; 29(1 Suppl 3):25-35. PubMed ID: 11894005
[TBL] [Abstract][Full Text] [Related]
14. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel in the management of advanced pancreatic cancer.
Lopes G; Rocha Lima CM
Semin Oncol; 2005 Apr; 32(2 Suppl 4):S10-23. PubMed ID: 16015551
[TBL] [Abstract][Full Text] [Related]
16. Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis.
Petrelli F; Parisi A; Tomasello G; Mini E; Arru M; Russo A; Garrone O; Khakoo S; Ardito R; Ghidini M
BMC Gastroenterol; 2023 Jun; 23(1):212. PubMed ID: 37337148
[TBL] [Abstract][Full Text] [Related]
17. The bioengineered and multifunctional nanoparticles in pancreatic cancer therapy: Bioresponisive nanostructures, phototherapy and targeted drug delivery.
Saadh MJ; Baher H; Li Y; Chaitanya M; Arias-Gonzáles JL; Allela OQB; Mahdi MH; Carlos Cotrina-Aliaga J; Lakshmaiya N; Ahjel S; Amin AH; Gilmer Rosales Rojas G; Ameen F; Ahsan M; Akhavan-Sigari R
Environ Res; 2023 Sep; 233():116490. PubMed ID: 37354932
[TBL] [Abstract][Full Text] [Related]
18. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
19. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]